Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 2008

View Archived Issues

Amyloid-beta protein dimers identified as cause of synapse impairment

Cara's peripherally active kappa opioid receptor agonist may be useful in treating visceral pain

New antidiabetic compounds described in recent patents

Effective antinociception without reward by novel endomorphin-1 analogue

VAP-1 ligands for diagnosing inflammatory disorders claimed in recent patent

Novel compounds with potential in the treatment of cancer disclosed

Mu opiod receptor agonist AS-006 effective in rat model of osteoarthritic pain

DiaMedica initiates enrollment in phase IIa clinical trial for DM-99 in type 2 diabetes

FDA approves Gen-Probe's supplemental regulatory application for Procleix Ultrio in HBV

SymBio and Eisai sign license agreement for bendamustine hydrochloride in Japan

Spectrum launches Fusilev injection and files amendment to NDA for tablet formulation

CV Therapeutics receives EMEA approval for Ranexa brand name

Abbott and AstraZeneca enter nonexclusive U.S. marketing agreement for Crestor

GTC and Ovation close agreement to develop and market ATryn in U.S

Nutra Pharma reports safety data from phase IIb/IIIa clinical study of RPI-78M in AMN

P-selectin inhibitor PSI-421 shows efficacy in models of vascular injury

Antisoma reports survival data from phase II study of ASA-404 in prostate cancer

FDA grants orphan drug designation to Santhera's omigapil in congenital muscular dystrophy

OrthoLogic completes dosing for phase Ib human clinical trial of AZX-100 in scarring

Seikagaku to initiate Japanese phase I clinical trial of CF-101 in rheumatoid arthritis

FDA approves Prestwick's Xenazine for chorea associated with Huntington's disease

Isis initiates phase I study of ISIS-353512 in healthy volunteers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...